ADARx Pharmaceuticals (NASDAQ:ADRX) Director Simeon George Buys 1,600,000 Shares of Company Stock

ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX) Director Simeon George bought 1,600,000 shares of the company’s stock in a transaction that occurred on Monday, September 28th. The stock was acquired at an average price of $17.00 per share, for a total transaction of $27,200,000.00. Following the completion of the acquisition, the director directly owned 5,554,094 shares in the company, valued at approximately $94,419,598. This represents a 40.46% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

ADARx Pharmaceuticals Stock Up 2.7%

Shares of NASDAQ ADRX traded up $0.55 during mid-day trading on Tuesday, hitting $20.64. 1,299,367 shares of the company traded hands, compared to its average volume of 1,252,283. ADARx Pharmaceuticals, Inc. has a 1 year low of $18.50 and a 1 year high of $23.21.

ADARx Pharmaceuticals Company Profile

ADARx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing RNA-based medicines for immune-mediated and other serious diseases. The company is headquartered in San Diego, California, and uses proprietary technologies designed to modulate disease-related proteins at the RNA level.

ADARx’s pipeline includes investigational therapies intended to address conditions involving the complement system, coagulation pathways and other biologic mechanisms. Its programs are designed to provide targeted, durable treatment through approaches such as RNA interference and related forms of RNA-based therapeutic intervention.

Founded in 2018, ADARx has advanced its drug candidates through preclinical and clinical development and has pursued regulatory and clinical activities in the United States and other international markets.